Emerging Topics in Pediatric Bone and Mineral Disorders 2008

Seminars in Nephrology

Volumn 29, Issue 4, 2009, Pages 370-378

  McKay, Charles P ^a   Portale, Anthony ^b  

^a CAROLINAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcimimetic; Calcium sensing receptor (CaSR); FGF 23; Phosphatonin

Indexed keywords

CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; SODIUM PHOSPHATE COTRANSPORTER 2C; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ARTICLE; AUTOSOMAL DOMINANT HYPOPARATHYROIDISM; AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; AUTOSOMAL RECESSIVE HYPOPHOSPHATEMIA; BARTTER SYNDROME; BONE DEMINERALIZATION; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EVENING DOSAGE; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; FAMILIAL HYPOPHOSPHATEMIC RICKETS; GENE MUTATION; HEMANGIOPERICYTOMA; HEMODIALYSIS; HEREDITARY HYPOPHOSPHATEMIC RICKETS WITH HYPERCALCIURIA; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERPARATHYROIDISM; HYPOCALCEMIA; HYPOCALCIURIA; HYPOPARATHYROIDISM; HYPOPHOSPHATEMIA; KIDNEY CALCIFICATION; KIDNEY TUBULE ABSORPTION; METABOLIC BONE DISEASE; NAUSEA AND VOMITING; NEONATAL SEVERE HYPERPARATHYROIDISM; ONCOGENIC OSTEOMALACIA; PARATHYROID HORMONE RELEASE; PARATHYROIDECTOMY; PERITONEAL DIALYSIS; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; TUMOR CALCINOSIS; X LINKED HYPOPHOSPHATEMIC RICKETS;

BONE AND BONES; CALCIUM; CHILD; CHILD, PRESCHOOL; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; MINERALS; OSTEOMALACIA; PHOSPHATES; RECEPTORS, CALCIUM-SENSING; RICKETS;

EID: 67650128062     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2009.03.020     Document Type: Article

References (56)

1. Chattopadhyay N., Mithal A., and Brown E. The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocr Rev 17 (1996) 289-307
2. Brown E.M., and MacLeod R.J. Extracellular calcium sensing and intracellular calcium signaling. Physiol Rev 81 (2001) 240-297
3. Hebert S.C. Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int 50 (1996) 2129-2139
4. Foley T.P., Harrison H.C., Arnaud C.D., and Harrison H.E. Familial benign hypercalcemia. J Pediatr 81 (1972) 1060-1067
5. Marx S.J., Attie M.F., Levine M.A., Spiegel A.M., Downs Jr. R.W., and Lasker R.D. The hypocalciuric or benign variant of familial hypercalcemia: clinical, and biochemical features in fifteen kindreds. Medicine 60 (1981) 397-412
6. Menko F.H., Bijvoet O.L.M., Fronen J.L.H.H., Sandler L.M., Adami S., O'Riordan J.L.H., et al. Familial benign hypercalcaemia. Q J Med 52 (1983) 120-140
7. Attie M.F., Gill J.R., Stock J.L., Spiegel A.M., Downs R.W., Levine M.A., et al. Urinary calcium excretion in familial hypocalciuric hypercalcemia. J Clin Invest 72 (1983) 667-676
8. Spiegel A.M., Harrison H.E., Marx S.J., Brown E.M., and Aurbach G.D. Neonatal primary hyperparathyroidism with autosomal dominant inheritance. J Pediatr 90 (1977) 269-272
9. Marx S.J., Attie M.F., Speigel A.M., Levine M.A., Lasker R.D., and Fox M. An association between neonatal severe primary hyperparathyroidism and familial hypocalciuric hypercalcemia in three kindreds. N Engl J Med 306 (1982) 257-264
10. Matsuo M., Okita K., Takemine H., and Fujita T. Neonatal primary hyperparathyroidism in familial hypocalciuric hypercalcemia. Am J Dis Child 136 (1982) 728-731
11. Cooper L., Wertheimer J., Levey R., Brown E., Leboff M., Wilkinson R., et al. Severe primary hyperparathyroidism in a neonate with two hypercalcemic parents: management with parathyroidectomy and heterotopic autotransplantation. Pediatrics 78 (1986) 263-268
12. Marx S.J., Fraser D., and Rapoport A. Familial hypocalciuric hypercalcemia. Mild expression of the gene in heterozygotes and severe expression in homozygotes. Am J Med 78 (1985) 15-22
13. 2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75 (1993) 1297-1303
14. Pearce S.H.S., Trump D., Wooding C., Besser G.M., Chew S.L., Grant D.B., et al. Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J Clin Invest 96 (1995) 2683-2692
15. Pollak M.R., Chou Y.-H.W., Marx S.J., Steinman B., Cole D.E.C., Brandi M.L., et al. Familial hypocalciuiric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J Clin Invest 93 (1994) 1108-1112
16. Matsuo M., Okita K., Takemine H., and Fujita T. Neonatal primary hyperparathyroidism in familial hypocalciuric hypercalcemia. Am J Dis Child 136 (1982) 728-731
17. Brown E.M. Mutant extracellular calcium-sensing receptors and severity of disease [editorial]. J Clin Endocrinol Metab 90 (2005) 1246-1248
18. Pollak M.R., Brown E.M., Estep H.L., McLaine P.N., Kifor O., Park J., et al. Autosomal dominant hypocalcemia cause by a Ca2+-sensing receptor gene mutation. Nat Genet 8 (1994) 303-307
19. Pearce S.H.S., Williamson C., Kifor O., Bai M., Coulthard M.G., Davies M., et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 335 (1996) 1115-1122
20. Watanabe S., Fukumoto S., Chang H., Takeuchi Y., Hasgawa Y., Okazaki R., et al. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 360 (2002) 692-694
21. Hebert S.C., Riccardi D., and Geibel J.P. The calcium-sensing receptor. In: Alpern R.J., and Hebert S.C. (Eds). Seldin and Giebisch's the kidney. 3rd ed. Vol 2 (2008), Elsevier Saunders, Philadelphia 1785-1802
22. Rodriguez M., Nemeth E., and Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 288 (2005) F253-F264
23. Goodman W.G., Veldhuis J.D., Belin T.R., Van Herle A.J., Juppner H., and Salusky I.B. Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J Clin Endocrinal Metab 83 (1998) 2765-2772
24. Cunningham J., Danese M., Olson K., Klassen P., and Chertow G.M. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68 (2005) 1793-1800
25. Evennpoel P. Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney Int 74 (2008) 265-275
26. Alon U., Levy-Olomucki R., Moore W.V., Stubbs J., Liu S., and Quarles L.D. Calcimimetics as an adjunctive treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 3 (2008) 658-664
27. Silverstein D., Kher K.K., Moudgil A., Khurana M., Wilcox J., and Moylan K. Cinacalcet is efficacious in pediatric dialysis patients. Pediatr Nephrol 23 (2008) 1817-1822
28. Muscheites J., Wigger M., Druekler E., Fischer D.-C., Kundt G., and Haffner D. Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr Nephrol 23 (2008) 1823-1829
29. Murer H., Hernando N., Forster I., and Biber J. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 80 (2000) 1373-1409
30. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26 (2000) 345-348
31. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 (2006) 770-774
32. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98 (2001) 6500-6505
33. The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11 (1995) 130-136
34. Jonsson K.B., Zahradnik R., Larsson T., White K.E., Sugimoto T., Imanishi Y., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348 (2003) 1656-1663
35. Perwad F., Azam N., Zhang M.Y., Yamashita T., Tenenhouse H.S., and Portale A.A. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146 (2005) 5358-5364
36. Econs M.J., and McEnery P.T. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82 (1997) 674-681
37. Imel E.A., Hui S.L., and Econs M.J. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22 (2007) 520-526
38. Kruse K., Woelfel D., Strom T.M., and Storm T.M. Loss of renal phosphate wasting in a child with autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation. Horm Res 55 (2001) 305-308
39. White K.E., Carn G., Lorenz-Depiereux B., Benet-Pages A., Strom T.M., and Econs M.J. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60 (2001) 2079-2086
40. Scriver C.R., Reade T., Halal F., Costa T., and Cole D.E. Autosomal hypophosphataemic bone disease responds to 1,25-(OH)2D3. Arch Dis Child 56 (1981) 203-207
41. Lorenz-Depiereux B., Bastepe M., et-Pages A., Amyere M., Wagenstaller J., Muller-Barth U., et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38 (2006) 1248-1250
42. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38 (2006) 1310-1315
43. Ye L., Mishina Y., Chen D., Huang H., Dallas S.L., Dallas M.R., et al. Dmp1-deficient mice display severe defects in cartilage formation responsible for a chondrodysplasia-like phenotype. J Biol Chem 280 (2005) 6197-6203
44. Tieder M., Modai D., Samuel R., Arie R., Halabe A., Bab I., et al. Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med 312 (1985) 611-617
45. Lorenz-Depiereux B., et-Pages A., Eckstein G., Tenenbaum-Rakover Y., Wagenstaller J., Tiosano D., et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 78 (2006) 193-201
46. Econs M.J., and Drezner M.K. Tumor-induced osteomalacia-unveiling a new hormone. N Engl J Med 330 (1994) 1679-1681
47. Hesse E., Moessinger E., Rosenthal H., Laenger F., Brabant G., Petrich T., et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res 22 (2007) 158-162
48. Topaz O., Shurman D.L., Bergman R., Indelman M., Ratajczak P., Mizrachi M., et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36 (2004) 579-581
49. Benet-Pages A., Lorenz-Depiereux B., Zischka H., White K.E., Econs M.J., and Strom T.M. FGF23 is processed by proprotein convertases but not by PHEX. Bone 35 (2004) 455-462
50. Larsson T., Davis S.I., Garringer H.J., Mooney S.D., Draman M.S., Cullen M.J., et al. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 146 (2005) 3883-3891
51. Ichikawa S., Imel E.A., Kreiter M.L., Yu X., Mackenzie D.S., Sorenson A.H., et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Musculoskelet Neuronal Interact 7 (2007) 318-319
52. Razzaque M.S., and Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 194 (2007) 1-10
53. Larsson T., Nisbeth U., Ljunggren O., Juppner H., and Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64 (2003) 2272-2279
54. Imanishi Y., Inaba M., Nakatsuka K., Nagasue K., Okuno S., Yoshihara A., et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65 (2004) 1943-1946
55. Gutierrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359 (2008) 584-592
56. Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18 (2007) 2600-2608